A Cluster Randomized Controlled Trial of an Enhanced Treatment Algorithm for the Management of Crohn's Disease.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Adalimumab; Antimetabolites
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms REACT2
- 06 Nov 2020 Biomarkers information updated
- 09 Oct 2013 Planned End Date changed from 1 Jul 2014 to 1 May 2015 as reported by ClinicalTrials.gov.
- 09 Oct 2013 Planned initiation date changed from 1 Oct 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.